Polly A. Murphy - 18 Jun 2026 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Reporting relationship: Director
Issuer ticker: AVIR
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 17:00:06 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrea Corcoran, as Attorney-in-Fact for Polly A. Murphy

Key filing fact

Polly A. Murphy filed Form 4 for Atea Pharmaceuticals, Inc. (AVIR) on 23 Jun 2026.

Key facts

This page summarizes Polly A. Murphy's Form 4 filing for Atea Pharmaceuticals, Inc. (AVIR).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 17:00.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001829248 Primary reporting owner

Murphy Polly A.

Relationship: Director
Address: 225 FRANKLIN STREET, SUITE 2100, BOSTON
Signature: /s/ Andrea Corcoran, as Attorney-in-Fact for Polly A. Murphy
Signature date: 23 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVIR transaction

Common Stock

Options Exercise

Transaction value
Shares: +29,600
Change %: +32%
Price: $0.000000^*
Shares after: 121,745
Date: 18 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVIR transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -29,600
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,600
Exercise price
Footnotes: F1, F2

AVIR transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +26,700
Change %
Price: $0.000000^*
Shares after: 26,700
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,700
Exercise price
Footnotes: F1, F3

AVIR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +37,700
Change %
Price: $0.000000^*
Shares after: 37,700
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,700
Exercise price: $4.36
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

The RSUs vested in full on June 18, 2026.

Footnote F3

The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F4

The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.